Serina Q3 10-Q: $19.4M Cash, Yet Going-Concern Doubt Persists
SER sits 24% above its 52-week low of $1.14 on light trading volume (0.4× avg).
Summary
Serina's Q3 10-Q shows $19.4 million of cash and a $21.2 million nine-month net loss, with management repeating substantial doubt about going concern despite this year's $21.2 million PIPE and ATM sales.
Key Events · Earnings and Guidance · SER
-
Going-Concern Doubt Reiterated
Management states that $19.4 million of cash at September 30, 2026 is not expected to fund operations for the twelve months following issuance of these statements.
-
Nine-Month Loss Widens to $21.2M
For the nine months ended September 30, 2026, the net loss was $21.2 million versus $15.9 million a year earlier, as R&D rose $1.9 million to $11.6 million and G&A rose $1.2 million to $9.4 million.
-
Roth Facility Is the Only Committed Backstop
At September 30, 2026, $23.1 million remained available under the $25.0 million Roth Committed Equity Facility, but sales are limited by NYSE American exchange caps, a 4.99% ownership blocker and a $0.50 minimum closing price.
-
NYSE American Compliance Plan Runs to July 2027
A January 9, 2026 deficiency notice led to a compliance plan accepted March 24, 2026; listing continues under quarterly review through July 9, 2027, with stockholders' equity now $13.9 million.
Analysis · SER · Life Sciences
The central fact for this clinical-stage company is that management still concludes cash will not fund operations for the twelve months after this filing, even after ending September with $19.4 million in cash. That balance reflects $21.2 million raised in the March 2026 PIPE, $10.2 million net from its ATM and $1.9 million from the Roth facility. Cash keeps draining as the SER-252 Phase 1b program advances, with $16.7 million used in operations over nine months. The only committed backstop is the $23.1 million remaining under the Roth facility, and it is capped by NYSE American exchange limits, a 4.99% ownership blocker and a $0.50 minimum price. A January 2026 stockholders' equity deficiency also keeps the company under an NYSE American compliance plan through July 9, 2027. Another equity raise is therefore the base case, and it would bring more dilution on top of a share count that already grew from 10.8 million to 26.4 million this year.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SER was trading at $1.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $35.8M. The 52-week trading range was $1.14 to $4.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.